Not medical advice. A record of published research and our assessments of it. The limits

Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity

Efficacy, Metabolic and Cardiovascular Effects of Liraglutide in Children Aged 6-12 Years With Severe Obesity: A Randomized Controlled Trial With Advanced Echocardiographic Assessment
NCT07590219 on ClinicalTrials.gov

Status: Active not recruitingResults none
Why it is watched: non-weight indication: cardiovascular
Who it enrolls: age 6 Years to 12 Years; no BMI minimum stated; conditions: Severe Obesity; Cardiovascular Function; Liraglutide; Childhood Obesity
Interventions: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Conditions: Severe Obesity; Cardiovascular Function; Liraglutide; Childhood Obesity; Echocardiography; Speckle Tracking
Phase and size: Phase 4 · 30 participants
Dates: Start 2024-03-30
Primary completion 2027-04
Sponsor: University of Sao Paulo General Hospital (Other)
Last checked: Sep 13, 2026

01Endpoints

What the trial will measure

Change in Body Mass Index (BMI)6 months

02Eligibility

Who can take part

Inclusion Criteria: * Children aged 6-12 years * BMI Z-score ≥ +3 * Previous unsuccessful lifestyle intervention Exclusion Criteria: * Severe chronic diseases * Cardiac disease * Dermatological contraindication * Use of interfering medications

03Change log

Registry changes

No changes recorded since the trial was added.